Lung Cancer Liquid Biopsy Global Market Report 2025

Description

Lung cancer liquid biopsy is a non-invasive method that examines blood or other bodily fluids to identify tumor-derived genetic material or cells. This technique supports early detection, genetic profiling, and monitoring of lung cancer by capturing cancer-specific biomarkers, providing an alternative to traditional surgical tissue biopsies.

Lung cancer liquid biopsy products include instruments, consumables kits and reagents, and software and services. Instruments refer to the hardware and analytical tools used to process and evaluate liquid biopsy samples. The technology applied includes multi-gene parallel analysis methods such as next-generation sequencing (NGS) and single-gene techniques like PCR and microarrays. Biomarkers analyzed include cell-free DNA, circulating tumor DNA, extracellular vesicles, circulating tumor cells, and other related indicators. These biomarkers are utilized for various purposes, including therapy selection, treatment monitoring, early cancer detection, recurrence surveillance, and other clinical applications. End-users include diagnostic and imaging centers, hospitals, academic and research institutions, and other relevant facilities.

The lung cancer liquid biopsy market research report is one of a series of new reports from The Business Research Company that provides lung cancer liquid biopsy market statistics, including the lung cancer liquid biopsy industry's global market size, regional shares, competitors with the lung cancer liquid biopsy market share, detailed lung cancer liquid biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer liquid biopsy market. This lung cancer liquid biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lung cancer liquid biopsy market size has grown rapidly in recent years. It will grow from $0.95 billion in 2024 to $1.12 billion in 2025 at a compound annual growth rate (CAGR) of 17.0%. Growth during the historic period can be attributed to the increasing prevalence of smoking- and pollution-related lung disorders, expanded use of liquid biopsy for treatment monitoring, growing investment in oncology research and development, rising demand for rapid and cost-effective diagnostic solutions, and an increasing number of clinical trials.

The lung cancer liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $2.08 billion in 2029 at a compound annual growth rate (CAGR) of 16.8%. Growth in the forecast period can be attributed to the rising incidence of lung cancer, increasing demand for non-invasive diagnostic methods, growing adoption of personalized medicine, heightened awareness of early cancer detection, and a rising geriatric population more vulnerable to cancer. Key trends expected during this period include advancements in circulating tumor DNA (ctDNA) analysis technologies, progress in exosome-based liquid biopsy techniques, innovations in microfluidics for isolating circulating tumor cells, the integration of AI and machine learning for biomarker interpretation, and technological breakthroughs enabling multiplex biomarker analysis.

The rising incidence of lung cancer is expected to drive the growth of the lung cancer liquid biopsy market in the coming years. Lung cancer is a condition marked by the uncontrolled proliferation of abnormal cells in the lungs, commonly linked to smoking and environmental exposures. The increasing number of cases is primarily attributed to continued tobacco use, which exposes the lungs to carcinogens that initiate abnormal cell growth. Liquid biopsy for lung cancer enables the detection of cancer-related genetic mutations and tumor DNA through a simple blood sample, facilitating early diagnosis, personalized treatment selection, and ongoing monitoring of disease progression or therapeutic response. For example, in 2023, the American Cancer Society reported that as of January 1, 2022, 654,620 individuals in the U.S. had a history of lung cancer, with many living with metastatic disease. Approximately 80% of these patients were aged 65 or older, and 55% had been diagnosed within the past five years, reflecting low survival rates. Consequently, the growing incidence of lung cancer is significantly contributing to the expansion of the lung cancer liquid biopsy market.

Major companies in the lung cancer liquid biopsy market are prioritizing technological advancements, such as the development of blood-based lung cancer screening tests, to improve early detection, enhance diagnostic accuracy, and provide non-invasive, real-time monitoring of tumor progression and treatment response. These blood-based screening tests analyze biomarkers in the bloodstream to detect lung cancer at an early stage, offering a less invasive alternative to traditional methods. For example, in October 2023, DELFI Diagnostics Inc., a U.S.-based biotechnology company, introduced FirstLook Lung-a blood-based liquid biopsy test aimed at early lung cancer detection. This test utilizes fragmentomics to identify early-stage lung cancer with high sensitivity and a 99.8% negative predictive value. It is designed to serve as an accessible and convenient initial screening tool for individuals at risk, with the goal of improving early detection rates, boosting screening participation, and helping prioritize imaging resources for those most likely to benefit.

In February 2024, Veracyte Inc., a U.S.-based molecular diagnostics company, acquired C2i Genomics Inc. for an undisclosed amount. Through this acquisition, Veracyte seeks to strengthen its cancer diagnostics portfolio by incorporating advanced whole-genome minimal residual disease (MRD) liquid biopsy technology to improve detection and monitoring across various cancer types. C2i Genomics Inc. is a U.S.-based company specializing in cancer detection and monitoring, including liquid biopsy tests for lung cancer.

Major players in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corp, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., MDxHealth SA, Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation.

North America was the largest region in the lung cancer liquid biopsy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lung cancer liquid biopsy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lung cancer liquid biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lung cancer liquid biopsy market consists of revenues earned by entities by providing services such as mutation detection and genomic profiling, treatment monitoring, and early diagnosis and screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The lung cancer liquid biopsy market also includes sales of NGS-based assays, CTC detection devices and others. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lung Cancer Liquid Biopsy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lung cancer liquid biopsy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lung cancer liquid biopsy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lung cancer liquid biopsy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Product: Instruments; Sconsumables Kits And Reagents; Software And Services
2) By Technology: Multi Gene-Parallel Analysis (Ngs); Single Gene Analysis (Pcr Microarrays)
3) By Biomarker: Cell-Free Deoxyribonucleic Acid; Circulating Tumor Deoxyribonucleic Acid; Extracellular Vesicles; Circulating Tumor Cells; Other Biomarkers
4) By Clinical Application: Therapy Selection; Treatment Monitoring; Early Cancer Screening; Recurrence Monitoring; Other Applications
5) By End User: Diagnostics And Imaging Centres; Hospitals; Academics And Research Centres; Other End Users
Subsegments:
1) By Instruments: Pcr Instruments; Microarray Instruments; Next-Generation Sequencing (Ngs) Instruments
2) By Consumables Kits And Reagents: Sample Collection Kits; Amplification Reagents; Sequencing Reagents
3) By Software And Services: Data Analysis Software; Cloud-Based Services; Bioinformatics Tools
Companies Mentioned: F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Biocept Inc.; Agilent Technologies Inc.; Eurofins Scientific
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r35961

1. Executive Summary

2. Lung Cancer Liquid Biopsy Market Characteristics

3. Lung Cancer Liquid Biopsy Market Trends And Strategies

4. Lung Cancer Liquid Biopsy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Lung Cancer Liquid Biopsy Growth Analysis And Strategic Analysis Framework

5.1. Global Lung Cancer Liquid Biopsy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Lung Cancer Liquid Biopsy Market Growth Rate Analysis
5.4. Global Lung Cancer Liquid Biopsy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Lung Cancer Liquid Biopsy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Lung Cancer Liquid Biopsy Total Addressable Market (TAM)

6. Lung Cancer Liquid Biopsy Market Segmentation

6.1. Global Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Instruments
Sconsumables Kits And Reagents
Software And Services
6.2. Global Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Multi Gene-Parallel Analysis (Ngs)
Single Gene Analysis (Pcr Microarrays)
6.3. Global Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cell-Free Deoxyribonucleic Acid
Circulating Tumor Deoxyribonucleic Acid
Extracellular Vesicles
Circulating Tumor Cells
Other Biomarkers
6.4. Global Lung Cancer Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Therapy Selection
Treatment Monitoring
Early Cancer Screening
Recurrence Monitoring
Other Applications
6.5. Global Lung Cancer Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diagnostics And Imaging Centres
Hospitals
Academics And Research Centres
Other End Users
6.6. Global Lung Cancer Liquid Biopsy Market, Sub-Segmentation Of Instruments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pcr Instruments
Microarray Instruments
Next-Generation Sequencing (Ngs) Instruments
6.7. Global Lung Cancer Liquid Biopsy Market, Sub-Segmentation Of Consumables Kits And Reagents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sample Collection Kits
Amplification Reagents
Sequencing Reagents
6.8. Global Lung Cancer Liquid Biopsy Market, Sub-Segmentation Of Software And Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Data Analysis Software
Cloud-Based Services
Bioinformatics Tools

7. Lung Cancer Liquid Biopsy Market Regional And Country Analysis

7.1. Global Lung Cancer Liquid Biopsy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Lung Cancer Liquid Biopsy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lung Cancer Liquid Biopsy Market

8.1. Asia-Pacific Lung Cancer Liquid Biopsy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lung Cancer Liquid Biopsy Market

9.1. China Lung Cancer Liquid Biopsy Market Overview
9.2. China Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lung Cancer Liquid Biopsy Market

10.1. India Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lung Cancer Liquid Biopsy Market

11.1. Japan Lung Cancer Liquid Biopsy Market Overview
11.2. Japan Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lung Cancer Liquid Biopsy Market

12.1. Australia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lung Cancer Liquid Biopsy Market

13.1. Indonesia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lung Cancer Liquid Biopsy Market

14.1. South Korea Lung Cancer Liquid Biopsy Market Overview
14.2. South Korea Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lung Cancer Liquid Biopsy Market

15.1. Western Europe Lung Cancer Liquid Biopsy Market Overview
15.2. Western Europe Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lung Cancer Liquid Biopsy Market

16.1. UK Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lung Cancer Liquid Biopsy Market

17.1. Germany Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lung Cancer Liquid Biopsy Market

18.1. France Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lung Cancer Liquid Biopsy Market

19.1. Italy Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lung Cancer Liquid Biopsy Market

20.1. Spain Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lung Cancer Liquid Biopsy Market

21.1. Eastern Europe Lung Cancer Liquid Biopsy Market Overview
21.2. Eastern Europe Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lung Cancer Liquid Biopsy Market

22.1. Russia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lung Cancer Liquid Biopsy Market

23.1. North America Lung Cancer Liquid Biopsy Market Overview
23.2. North America Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lung Cancer Liquid Biopsy Market

24.1. USA Lung Cancer Liquid Biopsy Market Overview
24.2. USA Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lung Cancer Liquid Biopsy Market

25.1. Canada Lung Cancer Liquid Biopsy Market Overview
25.2. Canada Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lung Cancer Liquid Biopsy Market

26.1. South America Lung Cancer Liquid Biopsy Market Overview
26.2. South America Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lung Cancer Liquid Biopsy Market

27.1. Brazil Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lung Cancer Liquid Biopsy Market

28.1. Middle East Lung Cancer Liquid Biopsy Market Overview
28.2. Middle East Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lung Cancer Liquid Biopsy Market

29.1. Africa Lung Cancer Liquid Biopsy Market Overview
29.2. Africa Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lung Cancer Liquid Biopsy Market Competitive Landscape And Company Profiles

30.1. Lung Cancer Liquid Biopsy Market Competitive Landscape
30.2. Lung Cancer Liquid Biopsy Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Biocept Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Eurofins Scientific Overview, Products and Services, Strategy and Financial Analysis

31. Lung Cancer Liquid Biopsy Market Other Major And Innovative Companies

31.1. Illumina Inc.
31.2. Sysmex Corporation
31.3. Bio-Rad Laboratories Inc.
31.4. QIAGEN N.V.
31.5. Exact Sciences Corp
31.6. Natera Inc.
31.7. Myriad Genetics Inc.
31.8. NeoGenomics Laboratories Inc.
31.9. Guardant Health Inc.
31.10. MDxHealth SA
31.11. Exosome Diagnostics Inc.
31.12. Menarini Silicon Biosystems S.p.A.
31.13. Inivata Ltd
31.14. Lucence Diagnostics Pte Ltd
31.15. LungLife AI Inc.

32. Global Lung Cancer Liquid Biopsy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lung Cancer Liquid Biopsy Market

34. Recent Developments In The Lung Cancer Liquid Biopsy Market

35. Lung Cancer Liquid Biopsy Market High Potential Countries, Segments and Strategies

35.1 Lung Cancer Liquid Biopsy Market In 2029 - Countries Offering Most New Opportunities
35.2 Lung Cancer Liquid Biopsy Market In 2029 - Segments Offering Most New Opportunities
35.3 Lung Cancer Liquid Biopsy Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer